Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.
The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 17, 25 | -0.44 Decreased by -140.00% | -1.19 Increased by +62.89% |
| Nov 4, 24 | -1.01 Increased by +28.37% | -1.42 Increased by +28.87% |
| Aug 5, 24 | -1.49 Decreased by -52.04% | -1.52 Increased by +1.97% |
| May 8, 24 | -1.43 Decreased by -113.43% | -1.33 Decreased by -7.52% |
| Feb 21, 24 | 1.10 Increased by +178.01% | -0.07 Increased by +1.67 K% |
| Nov 6, 23 | -1.41 Increased by +37.05% | -1.95 Increased by +27.69% |
| Aug 7, 23 | -0.98 Increased by +59.17% | -2.12 Increased by +53.77% |
| May 8, 23 | -0.67 Increased by +71.12% | -1.70 Increased by +60.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 35.00 M Decreased by -82.50% | -37.31 M Decreased by -141.76% | Decreased by -106.60% Decreased by -338.63% |
| Sep 30, 24 | 602.00 K Increased by +N/A% | -85.94 M Increased by +23.37% | Decreased by -14.28 K% Decreased by N/A% |
| Jun 30, 24 | 517.00 K Decreased by -99.26% | -126.41 M Decreased by -62.60% | Decreased by -24.45 K% Decreased by -21.92 K% |
| Mar 31, 24 | 504.00 K Decreased by -99.50% | -116.59 M Decreased by -119.71% | Decreased by -23.13 K% Decreased by -43.49 K% |
| Dec 31, 23 | 200.00 M Increased by +3.33 M% | 89.35 M Increased by +180.80% | Increased by +44.67% Increased by +100.00% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -112.15 M Increased by +35.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 70.00 M Increased by +44.20 K% | -77.74 M Increased by +58.17% | Decreased by -111.06% Increased by +99.91% |
| Mar 31, 23 | 100.00 M Increased by +56.08 K% | -53.06 M Increased by +70.39% | Decreased by -53.06% Increased by +99.95% |